Christian Heidbreder

Addiction treatment company Indivior PLC (NASDAQ: INDV) obtained exclusive global rights to develop, produce and commercialize Alar Pharmaceuticals’ portfolio of long-acting injectable formulations that release a prodrug1 of buprenorphine at varying durations, including its lead...

Indivior PLC (OTCPK:INVVY) (LON:INDV) announces the enrollment of the first patient in the Phase 2b study of AEF0117 for the treatment of cannabis use disorder (CUD). This follows less than a year after Indivior and Aelis Farma announced a strategic collaboration that includes an exclusive option...

Indivior PLC  (OTCPK:INVVY) (LON:INDV) published modeling data examining the competitive interaction between buprenorphine, a treatment for opioid use disorder, and fentanyl, a potent synthetic opioid, to better understand how buprenorphine can reduce fentanyl-induced respiratory depression....